SEATTLE, Nov. 22, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), is pleased to announce that Mark Reddish has joined its Management Team as Vice President of Product Development. Mark was formerly Vice President of Product Development and Principal Investigator, Biodefense at ID Biomedical, Bothell, WA, prior to the acquisition of the company by Glaxo SmithKline for $1.6 billion. At Biomira Inc, (renamed Oncothyreon) he was responsible for preclinical development of their cancer vaccines program where he led the early research and clinical development of Stimuvax, which is currently in late Stage 3 clinical trials under a partnership with Merck KGa.
Mark brings thirty years of biomedical experience ranging from clinical and academic research to industrial product development and has already brought significant value and insight to TapImmune as a member of the scientific advisory board. He has over 50 publications and a number of issued and pending patents in the area of vaccine technologies.
"Mark is a highly respected biotech operative with an impressive track record in taking leading immunotherapy products from early research through development, both in the areas of cancer vaccines and biodefense," said Dr Glynn Wilson, Chairman and CEO of TapImmune. "Mark will play a key role in our development operations and progression of our product pipeline as we open our own laboratories in Seattle in January 2012. We are fortunate to have someone with his breadth of experience join the Company."
"I am excited about this opportunity to work with the TAP related technologies as they address perhaps one of the most critical and potentially limiting steps in T cell responses to vaccines or to disease. For any vaccine candidate designed to stimulate a T cell response, T Cell Antigen Processing, or TAP is required. The TapImmune platform has an unlimited potential for partnering with a wide array of vaccines, be they therapeutic or prophylactic, cancer or anti-infectives."
About TapImmune Inc.
Taplmmune Inc. is a biotechnology company specializing in the development of innovative cell based immunotherapeutics and vaccines in the areas of oncology and infectious disease. The Company's lead product candidate, the AdhTAP vaccine is designed to restore and augment antigen presentation and subsequent recognition and killing of cancer cells by the immune system. The Company is currently planning the development AdhTAP for the commencement of clinical manufacturing and toxicology studies. The Company is also developing TAP-based prophylactic vaccines. As a vaccine component, the TAP technology has the potential to significantly improve the efficacy of current prophylactic vaccines and enhance the creation of new ones in the fight against pandemic infectious diseases.
The TapImmune Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3877
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.